Showing 2931-2940 of 5973 results for "".
- Revance's Injectable Toxin to Enter Phase 3 Trialshttps://practicaldermatology.com/news/revances-injectable-toxin-to-enter-phase-3-trials/2458500/It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second half of 2016. Revance is moving forward with an
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- It's Official: Botox Makes Us Feel Better About Ourselveshttps://practicaldermatology.com/news/its-official-botox-makes-us-feel-better-about-ourselves/2458516/Patient satisfaction with overall facial appearance increases by 28 percent with botulinum toxin type A injections to the glabellar rhytids, according to new research in the Aesthetic Surgery Journal. In the study, sati
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Dr. Ann Marshak-Rothstein Takes Home 2016 Lupus Insight Prize for Cutaneous Lupus Researchhttps://practicaldermatology.com/news/dr-ann-marshak-rothstein-takes-home-2016-lupus-insight-prize-for-cutaneous-lupus-research/2458520/Ann Marshak-Rothstein, PhD, a professor of Medicine/Rheumatology at the University of Massachusetts Medical received the 2016 Lupus Insight Prize for her research on cutaneous lupus. The award was announced at FOCIS 2016, the 16th Annual M
- Virtual Peer Pressure on Social Media May Up Indoor Tanning in Young Womenhttps://practicaldermatology.com/news/virtual-peer-pressure-on-social-media-may-up-indoor-tanning-in-young-women/2458523/Use of Twitter and Instagram may be driving an uptick in indoor tanning among young adult women, a new study suggests. The study, which appears in the July issue of the Journal of the American Academ
- Regenica® Rejuvenating Dual Serum Improves Skin Texture, Tone Through 90 Dayshttps://practicaldermatology.com/news/regenica-rejuvenating-dual-serum-improves-skin-texture-tone-through-90-days/2458521/New research shows that Regenica® Rejuvenating Dual Serum starts working at as early as 14 days, with continued improvement seen through 90 days. In the study, statistically significant improvements were reported as early as 14 days, wi
- Sciton Introduces diVa Laser for Vaginal Rejuvenationhttps://practicaldermatology.com/news/sciton-introduced-diva-laser-for-vaginal-rejuvenation/2458524/Sciton introduced diVa, a hybrid fractional laser (HFL) for the treatment of vaginal tissue. Major life events like childbirth and menopause can cause changes in vaginal health. Excessive stretching of the vaginal tissue commonly happens from childbirth. Vaginal tissue may not fully recov
- Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Directorhttps://practicaldermatology.com/news/valeant-pharmaceuticals-appoints-thomas-w-ross-sr-lead-independent-director/2458532/Valeant Pharmaceuticals International, Inc.'s Board of Directors appointed Thomas W. Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since March 8, 2016, serves on the Board&#
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to